Fortunately, cell proliferation and carcinogenic growth uncontrollably caused by HER2 gene mutations can be effectively suppressed with a regimen of special HER2-directed agents (e.g., neratinib), providing an additional treatment strategy for breast cancer (18, 19). This evidence concerns the gene ERBB2 and breast carcinoma.